N-(5-tert-butyl-4-methylthiazol-2-yl)-4-methyl-3-(3-methyl-1-(6-(4-methylpiperazin-1-ylamino)-pyrimidin-4-yl)-1H-pyrazol-5-ylamino)-benzamide | 1018470-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: N-(5-tert-butyl-4-methylthiazol-2-yl)-4-methyl-3-(3-methyl-1-(6-(4-methylpiperazin-1-ylamino)-pyrimidin-4-yl)-1H-pyrazol-5-ylamino)-benzamide
• 英文别名: N-(5-tert-butyl-4-methyl-1,3-thiazol-2-yl)-4-methyl-3-[[5-methyl-2-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]pyrazol-3-yl]amino]benzamide
• CAS: 1018470-23-9
• 化学式: C₂₉H₃₈N₁₀OS
• 分子量: 574.753
• InChiKey: FKTUIRYZOLIIPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  144
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• [EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
  申请人：GLAXO GROUP LTD

  公开号：WO2009026197A1

  公开（公告）日：2009-02-26

  The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.

  这项发明涉及到符合以下式（I）的化合物，其中R1、R2a、R2b、R2c、R3和n的定义如下，并且其药用盐。它们是半胱氨酸蛋白酶C抑制剂，可用于治疗由半胱氨酸蛋白酶C酶介导的疾病，如慢性阻塞性肺病。
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：Albaugh Pamela

  公开号：US20100029605A1

  公开（公告）日：2010-02-04

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.

  本发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调激酶活性相关的疾病或疾病的方法，特别是涉及Abl、ARG、BCR-Abl、BRK、EphB、Fms、Fyn、KDR、c-Kit、LCK、PDGF-R、b-Raf、c-Raf、SAPK2、Src、Tie2和TrkB激酶异常激活的疾病或疾病。
• US8202876B2
  申请人：——

  公开号：US8202876B2

  公开（公告）日：2012-06-19
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：IRM LLC

  公开号：WO2008042639A1

  公开（公告）日：2008-04-10

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.
  [FR] La présente invention concerne une nouvelle classe de composés, des compositions pharmaceutiques contenant de tels composés et des procédés d'utilisation desdits composés pour traiter ou prévenir des maladies ou des troubles associés à une activité kinase anormale ou déréglée, particulièrement les maladies ou les troubles qui impliquent l'activation anormale des kinases Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 et TrkB.